Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
BioArctic AB Class B ( ($SE:BIOA.B) ) has provided an announcement.
BioArctic AB has received a positive opinion from the European Medicines Agency for orphan medicinal product designation for exidavnemab, a treatment for Multiple System Atrophy (MSA), a rare and fatal neurodegenerative disease. This designation provides incentives for developing treatments for rare diseases, potentially enhancing BioArctic’s market positioning and offering hope for addressing high unmet medical needs in MSA and related disorders.
More about BioArctic AB Class B
BioArctic AB is a Swedish research-based biopharmaceutical company that focuses on developing innovative treatments for neurodegenerative diseases. They are known for originating Leqembi®, a drug that slows the progression of Alzheimer’s disease. The company has a broad research portfolio that includes Alzheimer’s, Parkinson’s, ALS, and enzyme deficiency diseases, utilizing proprietary technology to improve drug transport into the brain. BioArctic’s B share is listed on Nasdaq Stockholm Large Cap.
Average Trading Volume: 290,954
Current Market Cap: SEK16.38B
See more insights into BIOA.B stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue